Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 6040149, 11 pages
https://doi.org/10.1155/2018/6040149
Research Article

Identification of Estrogen Receptor α Antagonists from Natural Products via In Vitro and In Silico Approaches

1Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Xian Nong Tan Street, Beijing 100050, China
2Beijing Key Laboratory of Drug Target Research and Drug Screening, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
3State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Correspondence should be addressed to Ai-Lin Liu; nc.ca.mmi@niliauil and Guan-Hua Du; nc.ca.mmi@hgud

Xiaocong Pang and Weiqi Fu contributed equally to this work.

Received 15 February 2018; Revised 1 April 2018; Accepted 11 April 2018; Published 10 May 2018

Academic Editor: Valentina Pallottini

Copyright © 2018 Xiaocong Pang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Nilsson and J.-Å. Gustafsson, “Estrogen receptors: therapies targeted to receptor subtypes,” Clinical Pharmacology & Therapeutics, vol. 89, no. 1, pp. 44–55, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Hall, J. F. Couse, and K. S. Korach, “The multifaceted mechanisms of estradiol and estrogen receptor signaling,” Journal of Biological Chemistry, vol. 276, no. 40, pp. 36869–36872, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Ishihara, K. Itoh, A. Ishida, and T. Yamazaki, “Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 145, pp. 85–93, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. P. A. Arias-Loza, M. Muehlfelder, and T. Pelzer, “Estrogen and estrogen receptors in cardiovascular oxidative stress,” Pflügers Archiv - European Journal of Physiology, vol. 465, no. 5, pp. 739–746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Paterni, C. Granchi, J. A. Katzenellenbogen, and F. Minutolo, “Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential,” Steroids, vol. 90, pp. 13–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Zhang, P. Liu, H. Chen et al., “Characterization of a selective inverse agonist for estrogen related receptor α as a potential agent for breast cancer,” European Journal of Pharmacology, vol. 789, pp. 439–448, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. B. B. Busch, W. C. Stevens, R. Martin et al., “Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor α,” Journal of Medicinal Chemistry, vol. 47, no. 23, pp. 5593–5596, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. W. F. Anderson, N. Chatterjee, W. B. Ershler, and O. W. Brawley, “Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database,” Breast Cancer Research and Treatment, vol. 76, no. 1, pp. 27–36, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Ascenzi, A. Bocedi, and M. Marino, “Structure–function relationship of estrogen receptor α and β: impact on human health,” Molecular Aspects of Medicine, vol. 27, no. 4, pp. 299–402, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. H. S. Ranhotra, “Estrogen-related receptor alpha and cancer: axis of evil,” Journal of Receptor and Signal Transduction Research, vol. 35, no. 6, pp. 505–508, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. F. E. May, “Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer,” Cancer Management and Research, vol. 6, pp. 225–252, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. R. A. Stein and D. P. McDonnell, “Estrogen-related receptor α as a therapeutic target in cancer,” Endocrine-Related Cancer, vol. 13, Supplement 1, pp. S25–S32, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Shang and M. Brown, “Molecular determinants for the tissue specificity of SERMs,” Science, vol. 295, no. 5564, pp. 2465–2468, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. V. C. Jordan, “Chemoprevention of breast cancer with selective oestrogen-receptor modulators,” Nature Reviews Cancer, vol. 7, no. 1, pp. 46–53, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. F. E. van Leeuwen, A. W. van den Belt-Dusebout, F. E. van Leeuwen et al., “Risk of endometrial cancer after tamoxifen treatment of breast cancer,” The Lancet, vol. 343, no. 8895, pp. 448–452, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Shou, S. Massarweh, C. K. Osborne et al., “Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer,” Journal of the National Cancer Institute, vol. 96, no. 12, pp. 926–935, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Wang, Q. You, F. S. Huang, and H. Xiang, “Recent advances in selective estrogen receptor modulators for breast cancer,” Mini-Reviews in Medicinal Chemistry, vol. 9, no. 10, pp. 1191–1201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. D. D. Baker, M. Chu, U. Oza, and V. Rajgarhia, “The value of natural products to future pharmaceutical discovery,” Natural Product Reports, vol. 24, no. 6, pp. 1225–1244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Y.-C. Chen, “TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico,” PLoS One, vol. 6, no. 1, article e15939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Xue, Z. Fang, M. Zhang, Z. Yi, C. Wen, and T. Shi, “TCMID: Traditional Chinese Medicine integrative database for herb molecular mechanism analysis,” Nucleic Acids Research, vol. 41, no. D1, pp. D1089–D1095, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Huang and J. H. Wang, “CEMTDD: Chinese Ethnic Minority Traditional Drug Database,” Apoptosis, vol. 19, no. 9, pp. 1419-1420, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. U. Schmidt, S. Struck, B. Gruening et al., “SuperToxic: a comprehensive database of toxic compounds,” Nucleic Acids Research, vol. 37, Supplement 1, pp. D295–D299, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Dunkel, M. Fullbeck, S. Neumann, and R. Preissner, “SuperNatural: a searchable database of available natural compounds,” Nucleic Acids Research, vol. 34, Supplement 1, pp. D678–D683, 2006. View at Publisher · View at Google Scholar
  25. T. Xie, S. Song, S. Li, L. Ouyang, L. Xia, and J. Huang, “Review of natural product databases,” Cell Proliferation, vol. 48, no. 4, pp. 398–404, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. H. H. Xiao, C. Y. Fung, S. K. Mok et al., “Flavonoids from Herba epimedii selectively activate estrogen receptor alpha (ERα) and stimulate ER-dependent osteoblastic functions in UMR-106 cells,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 143, pp. 141–151, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. W. L. Jorgensen, “The many roles of computation in drug discovery,” Science, vol. 303, no. 5665, pp. 1813–1818, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. P. S. Kharkar, M. E. A. Reith, and A. K. Dutta, “Three-dimensional quantitative structure-activity relationship (3D QSAR) and pharmacophore elucidation of tetrahydropyran derivatives as serotonin and norepinephrine transporter inhibitors,” Journal of Computer-Aided Molecular Design, vol. 22, no. 1, pp. 1–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. N. Lima, E. A. Philot, G. H. G. Trossini, L. P. B. Scott, V. G. Maltarollo, and K. M. Honorio, “Use of machine learning approaches for novel drug discovery,” Expert Opinion on Drug Discovery, vol. 11, no. 3, pp. 225–239, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Lavecchia, “Machine-learning approaches in drug discovery: methods and applications,” Drug Discovery Today, vol. 20, no. 3, pp. 318–331, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Liu, Y. Lin, X. Wen, R. N. Jorissen, and M. K. Gilson, “BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities,” Nucleic Acids Research, vol. 35, Supplement 1, pp. D198–D201, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. M. Mysinger, M. Carchia, J. J. Irwin, and B. K. Shoichet, “Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking,” Journal of Medicinal Chemistry, vol. 55, no. 14, pp. 6582–6594, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Fang, R. Yang, L. Gao et al., “Predictions of BuChE inhibitors using support vector machine and naive Bayesian classification techniques in drug discovery,” Journal of Chemical Information and Modeling, vol. 53, no. 11, pp. 3009–3020, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Kong, D. Qu, X. Chen, Y. N. Gong, and A. Yan, “Self-organizing map (SOM) and support vector machine (SVM) models for the prediction of human epidermal growth factor receptor (EGFR/ ErbB-1) inhibitors,” Combinatorial Chemistry & High Throughput Screening, vol. 19, no. 5, pp. 400–411, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Xia, E. G. Maliski, P. Gallant, and D. Rogers, “Classification of kinase inhibitors using a Bayesian model,” Journal of Medicinal Chemistry, vol. 47, no. 18, pp. 4463–4470, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Chen, Y. Li, Q. Zhao, H. Peng, and T. Hou, “ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques,” Molecular Pharmaceutics, vol. 8, no. 3, pp. 889–900, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. K. Shiau, D. Barstad, P. M. Loria et al., “The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen,” Cell, vol. 95, no. 7, pp. 927–937, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. M. Salmani, H. Lv, S. Asghar, and J. Zhou, “Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin,” Pharmaceutical Development and Technology, vol. 20, no. 4, pp. 465–472, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. X. Pang, L. Wang, D. Kang et al., “Effects of P-glycoprotein on the transport of DL0410, a potential multifunctional anti-Alzheimer agent,” Molecules, vol. 22, no. 8, p. 1246, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Pang, H. Fu, S. Yang et al., “Evaluation of novel dual acetyl- and butyrylcholinesterase inhibitors as potential anti-Alzheimer’s disease agents using pharmacophore, 3D-QSAR, and molecular docking approaches,” Molecules, vol. 22, no. 8, p. 1254, 2017. View at Publisher · View at Google Scholar · View at Scopus
  41. S. P. Niinivehmas, E. Manivannan, S. Rauhamäki, J. Huuskonen, and O. T. Pentikäinen, “Identification of estrogen receptor α ligands with virtual screening techniques,” Journal of Molecular Graphics and Modelling, vol. 64, pp. 30–39, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. Q. Zhang, M. Lu, C. Wang, J. Du, P. Zhou, and M. Zhao, “Characterization of estrogen receptor α activities in polychlorinated biphenyls by in vitro dual-luciferase reporter gene assay,” Environmental Pollution, vol. 189, pp. 169–175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Cheng, W. Li, Y. Zhou et al., “admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties,” Journal of Chemical Information and Modeling, vol. 52, no. 11, pp. 3099–3105, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. Z. Tang, C. Wu, T. Wang et al., “Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents,” European Journal of Medicinal Chemistry, vol. 118, pp. 328–339, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Ohta, Y. Chiba, A. Kaise, and Y. Endo, “Structure–activity relationship study of diphenylamine-based estrogen receptor (ER) antagonists,” Bioorganic & Medicinal Chemistry, vol. 23, no. 4, pp. 861–867, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Li, C. Tang, Z. Hu et al., “Synthesis and structure–activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy,” Bioorganic & Medicinal Chemistry, vol. 24, no. 13, pp. 3062–3074, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Nagata, “Factors to consider in the association between soy isoflavone intake and breast cancer risk,” Journal of Epidemiology, vol. 20, no. 2, pp. 83–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Sureda, A. Sanches Silva, D. I. Sánchez-Machado et al., “Hypotensive effects of genistein: from chemistry to medicine,” Chemico-Biological Interactions, vol. 268, pp. 37–46, 2017. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Saha, P. Sadhukhan, S. Mahalanobish, S. Dutta, and P. C. Sil, “Ameliorative role of genistein against age-dependent chronic arsenic toxicity in murine brains via the regulation of oxidative stress and inflammatory signaling cascades,” The Journal of Nutritional Biochemistry, vol. 55, pp. 26–40, 2017. View at Publisher · View at Google Scholar
  50. Z. Papoutsi, E. Kassi, A. Tsiapara, N. Fokialakis, G. P. Chrousos, and P. Moutsatsou, “Evaluation of estrogenic/antiestrogenic activity of ellagic acid via the estrogen receptor subtypes ERα and ERβ,” Journal of Agricultural and Food Chemistry, vol. 53, no. 20, pp. 7715–7720, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. E. J. Lee, J. L. Kim, Y. H. Kim, M. K. Kang, J. H. Gong, and Y. H. Kang, “Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice,” Phytomedicine, vol. 21, no. 10, pp. 1208–1215, 2014. View at Publisher · View at Google Scholar · View at Scopus